Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › AJANTPHARM

AJANTPHARM

Ajanta Pharma Limited
Mid-capPharma ↗

What the six lenses say about AJANTPHARM — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹3307.6
2026-07-10
VWAP · 1Y anchor
₹2812
+17.6% from VWAP
P/E · TTM
39.1×
TTM EPS ₹84.5
52-week range
89%
position low→high
RSI(14)
58
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How AJANTPHARM’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.0
avg conviction decile
Leadership
0/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD890›

The actual numbers

Price vs VWAP (1y)+17.6%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+14.3%
Price vs 50-EMA+5.6%
RSI(14)58
RS vs Nifty 500 · 3M+14.6%
RS vs sector · 3M+2.1%
52-week range89%
Volume vs 30d avg0.37×
Volume vs 60d avg0.40×
ATR(14) · volatility114.4
Bollinger width · vol contraction0.149
FundamentalD1085›

The actual numbers

Return on equity (ROE)27.1%
Return on capital (ROCE)34.5%
Operating margin25.5%
Net margin19.4%
Revenue growth · YoY+17.3%
EPS growth · YoY+15.1%
Debt / equity0.06×

Full 8-quarter history in the financials table below.

ValuationD314›

The actual numbers

P/E (TTM)39.1×
TTM EPS₹84.5
52-week range89%
CatalystD122›

The actual numbers

Earnings & momentum15
Capital actions11
Governance70

Every filing in the corporate-announcements panel below.

FlowD450›

The actual numbers

Promoter holding66.3%
Delivery · 30d avg49.5%
Up/down-day asymmetry1.7pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D8 + D4 ) ÷ 2 = 6.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
86
Conviction score 86/100 · avg-decile strength 6.0/10
Conviction score86/100›
TechnicalD8›
FundamentalD10›
ValuationD3›
CatalystD1›
FlowD4›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.5pp
-0.2pp
+4.3pp
+18.2pp
+26.3pp
+33.1pp
Nifty 500
Broad-market baseline
+0.1pp
-0.3pp
+3.8pp
+14.6pp
+21.3pp
+29.3pp
Sector
Own-sector index
—
—
+1.4pp
+2.1pp
+6.9pp
+11.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

AJANTPHARM daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
3307.60+28.80

Relative strength

RS vs baseline · rebased to 100

AJANTPHARM ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
145.99+0.18

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,1451,1871,1461,1701,3031,3541,3751,422
↳ change QoQ—+3.6%-3.4%+2.1%+11.4%+3.9%+1.6%+3.4%
EBITDA (₹cr)357331351297351328382333
EBITDA margin31.2%27.9%30.6%25.4%26.9%24.2%27.8%23.4%
PAT (₹cr)246216233225255260274267
↳ change QoQ—-11.9%+7.6%-3.4%+13.3%+2.0%+5.4%-2.6%
Net margin21.5%18.2%20.3%19.2%19.6%19.2%19.9%18.8%
EPS (₹)19.5417.2718.6018.0320.4420.8321.9121.35
D/E————————
YoY growth · Mar '26Revenue +21.5% YoYPAT +18.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 15 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 19 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 19 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 22 Apr '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Apr '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Apr '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 9 Mar '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Feb '26
    LOWgovernance
    Rumour Verification - Regulation 30(11)
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Feb '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds AJANTPHARM

Mutual funds holding AJANTPHARM (10)

FundWeightAUM ₹crGrade
Nippon India Small Cap Gr Bns0.73%78,407
Nippon India Small Cap Gr0.73%78,407
Nippon India Small Cap Dir Bns0.73%78,407
Kotak Flexicap Reg Gr0.99%55,850
Kotak Large & Midcap Reg Gr1.08%31,263
HDFC Large and Mid Cap Gr0.92%28,515
Canara Robeco Large & Mid Cap Reg Gr0.56%25,251
UTI Flexi Cap Reg Gr2.02%22,882
SBI Flexicap Reg Gr0.65%22,685
Kotak Small Cap Reg Gr2.10%18,691

ETFs holding AJANTPHARM (3)

ETFWeightGrade
Nippon India Nifty Pharma ETF1.56%
Mirae Asset Nifty 500 Healthcare ETF0.98%
Motilal Oswal BSE Healthcare ETF0.84%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma